Sugi Predict

Sugi Predict / Compounds / SCHEMBL2587892

SCHEMBL2587892

SCHEMBL2587892

CC(C)(C)[Si](OC[C@H]1O[C@H](O)[C@H]2O[C@@H]21)(c1ccccc1)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ SMYD2 Q9NRG4 3/20 0.35
▸ CYP3A4 P08684 2/20 0.32
▸ HTT P42858 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12277057 0.87 ALDH1A1 (0.42) SMYD2CYP3A4HTTSMN1; SMN2ALDH1A1
SCHEMBL19464883 0.87 ALDH1A1 (0.42) SMYD2CYP3A4HTTSMN1; SMN2ALDH1A1
SCHEMBL866009 0.87 ALDH1A1 (0.42) SMYD2CYP3A4HTTSMN1; SMN2ALDH1A1
SCHEMBL4309745 0.87 ALDH1A1 (0.42) SMYD2CYP3A4HTTSMN1; SMN2ALDH1A1
SCHEMBL16707269 0.87 ALDH1A1 (0.42) SMYD2CYP3A4HTTSMN1; SMN2ALDH1A1
SCHEMBL12803239 0.87 ALDH1A1 (0.42) SMYD2CYP3A4HTTSMN1; SMN2ALDH1A1
SCHEMBL12936593 0.87 ALDH1A1 (0.42) SMYD2CYP3A4HTTSMN1; SMN2ALDH1A1
SCHEMBL1842894 0.85 SMYD2 (0.36) SMYD2CYP3A4HTTSMN1; SMN2
SCHEMBL1842898 0.85 SMYD2 (0.36) SMYD2CYP3A4HTTSMN1; SMN2
SCHEMBL17822565 0.85 SMYD2 (0.36) SMYD2CYP3A4HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10100076-B2 Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation GILEAD PHARMASSET LLC (US) 2018-10-16 — — US disclosed
US-20140057863-A1 MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION GILEAD SCIENCES, INC. (US) 2014-02-27 — — US disclosed
EP-2251015-B1 Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation GILEAD PHARMASSET LLC (US) 2013-02-20 — — EP disclosed
US-20110269707-A1 Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation PHARMASSET, INC. 2011-11-03 — — US disclosed
EP-1411954-B1 MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION PHARMASSET INC (US) 2010-12-15 — — EP disclosed
EP-2251015-A1 Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation Pharmasset, Inc. (US) 2010-11-17 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140057863-A1 MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION SLC29A1, PNP, SLC29A2 SMYD2 2435/4885CYP3A4 298/4885HTT 4480/4885
US-20110269707-A1 Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation PNP, ALPP, XDH SMYD2 2666/4885CYP3A4 967/4885HTT 4766/4885
US-10100076-B2 Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation SLC29A1, SLC29A2, PNP SMYD2 2535/4885CYP3A4 592/4885HTT 4514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.